FDA grants ODD to Candel Therapeutics’ pancreatic cancer treatment
Betsy Goodfellow | April 15, 2024 | News story | Medical Communications | Candel Therapeutics, FDA, ODD, Oncology, Pancreatic cancer
Candel Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to CAN-2409, Candel’s immunotherapy candidate, for the treatment of pancreatic cancer.
Candel has previously reported updated overall survival data from its ongoing phase 2 clinical trial of CAN-2409 plus valacyclovir, along with standard of care chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma (PDAC). This data showed a ‘notable improvement in estimated median overall survival of 28.8 months after experimental treatment with CAN-2409 versus only 12.5 months in the control group’, according to the company’s press release.
Paul Peter Tak MD PhD FMedSci, president and chief executive officer of Candel Therapeutics, commented: “We recently reported data from the phase 2 randomised clinical trial of CAN-2409 in borderline resectable pancreatic cancer, showing that CAN-2409, when added to standard of care, more than doubled the median overall survival obtained with standard of care alone. We are pleased that the FDA has now granted Candel with both Orphan Drug and Fast Track Designation to this programme, as we seek to reshape the treatment paradigm in pancreatic cancer.”
The drug has been generally well tolerated, with no new safety signals being observed throughout the trial, and no dose-limiting toxicities or cases of pancreatitis.
Betsy Goodfellow
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
